Background. Bacillus Calmette–Guerin polysaccharide nucleic acid (BCG-PSN), as an immune modulator, can effectively regulate the immune function of the body, control the release of histamine inflammatory substances, and achieve allergic effects against chronic spontaneous urticaria (CSU). This study aimed to evaluate the effectiveness of BCG-PSN on the levels of inflammatory factors and Th1/Th2 differentiation in CSU. Methods. A systemic literature search of BCG-PSN treatment of CSU was performed using the PubMed, Cochrane Library, Web of Science, CBM, and other databases. A quantitative meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Review manager software 5.4 was used for meta-analysis. Results. Twenty-seven studies pertaining to 2840 patients were included. The duration of treatment was 4 to 12 weeks. BCG-PSN can increase CD3+T levels (MD = 6.06; 95% CI: 5.30 to 6.82; < 0.00001; I2 = 31%), CD4+T levels (MD = 5.41; 95% CI: 4.82 to 6.01; < 0.00001; I2 = 40%), and CD4+/CD8+(MD = 0.33; 95% CI: 0.28 to 0.38; < 0.00001; I2 = 15%); at the same time, BCG-PSN can downregulate CD8+T levels (MD = −3.28; 95% CI: −3.82 to −2.74; < 0.00001; I2 = 32%). Furthermore, BCG-PSN could downregulate IL-4 levels (MD = −4.06, 95% CI: −5.15 to −2.97, < 0.00001; I2 = 0%), TNF-α levels (MD = −2.34; 95% CI: −3.01 to −1.66; < 0.00001; I2 = 26%) and upregulate IL-10 levels (MD = 25.59, 95% CI: 23.50 to 27.69, < 0.00001; I2 = 0%) and INF-γ levels (MD = 4.62, 95% CI: 3.79 to 5.45, < 0.00001; I2 = 5%). Conclusions. BCG-PSN can regulate the levels of inflammatory factors and Th1/Th2 differentiation in CSU. However, the long-term effectiveness and more objective experimental indicators of BCG-PSN remain to be further studied. Trial Registration. This trial is registered with PROSPERO ID: CRD42022332475.
{"title":"Effects of BCG-PSN on the Levels of Inflammatory Factors and Th1/Th2 Differentiation in Chronic Spontaneous Urticaria: Meta-Analysis and Systematic Review","authors":"Qiang Fu, Fu-Jun Huang, Zi-Wenyan Zhou, Lei Tang, Qi Zheng, Miao Zhang, Xun Zhou","doi":"10.1155/2023/2917144","DOIUrl":"https://doi.org/10.1155/2023/2917144","url":null,"abstract":"Background. Bacillus Calmette–Guerin polysaccharide nucleic acid (BCG-PSN), as an immune modulator, can effectively regulate the immune function of the body, control the release of histamine inflammatory substances, and achieve allergic effects against chronic spontaneous urticaria (CSU). This study aimed to evaluate the effectiveness of BCG-PSN on the levels of inflammatory factors and Th1/Th2 differentiation in CSU. Methods. A systemic literature search of BCG-PSN treatment of CSU was performed using the PubMed, Cochrane Library, Web of Science, CBM, and other databases. A quantitative meta-analysis was conducted according to the guidelines of the Cochrane Handbook. Review manager software 5.4 was used for meta-analysis. Results. Twenty-seven studies pertaining to 2840 patients were included. The duration of treatment was 4 to 12 weeks. BCG-PSN can increase CD3+T levels (MD = 6.06; 95% CI: 5.30 to 6.82; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> </math> < 0.00001; I2 = 31%), CD4+T levels (MD = 5.41; 95% CI: 4.82 to 6.01; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> </math> < 0.00001; I2 = 40%), and CD4+/CD8+(MD = 0.33; 95% CI: 0.28 to 0.38; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> </math> < 0.00001; I2 = 15%); at the same time, BCG-PSN can downregulate CD8+T levels (MD = −3.28; 95% CI: −3.82 to −2.74; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> </math> < 0.00001; I2 = 32%). Furthermore, BCG-PSN could downregulate IL-4 levels (MD = −4.06, 95% CI: −5.15 to −2.97, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M5\"> <mi>p</mi> </math> < 0.00001; I2 = 0%), TNF-α levels (MD = −2.34; 95% CI: −3.01 to −1.66; <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M6\"> <mi>p</mi> </math> < 0.00001; I2 = 26%) and upregulate IL-10 levels (MD = 25.59, 95% CI: 23.50 to 27.69, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M7\"> <mi>p</mi> </math> < 0.00001; I2 = 0%) and INF-γ levels (MD = 4.62, 95% CI: 3.79 to 5.45, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M8\"> <mi>p</mi> </math> < 0.00001; I2 = 5%). Conclusions. BCG-PSN can regulate the levels of inflammatory factors and Th1/Th2 differentiation in CSU. However, the long-term effectiveness and more objective experimental indicators of BCG-PSN remain to be further studied. Trial Registration. This trial is registered with PROSPERO ID: CRD42022332475.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135394208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yingyuan Yu, Dawei Huang, Yuxiong Jiang, Jiajing Lu, Lian Cui, Rongfen Chen, Ying Li, Yuling Shi
Background. Occult psoriatic arthritis (PsA) refers to a subset of psoriasis patients showing lesions on imaging but do not exhibit arthritis symptoms. Objective. This study was aimed to discover a simple biomarker that could be easily incorporated in clinical practice to identify occult PsA patients, defined as psoriasis patients with lesions on imaging but without arthritis symptoms, among silent psoriasis (PsO) patients, defined as psoriasis patients without any arthritis symptoms. Methods. A total of 149 silent PsO patients, including 83 PsO alone patients, defined as psoriasis patients without any arthritis symptoms and evidence of lesions on imaging, and 66 occult PsA patients, were enrolled in this cross-sectional study, and they all underwent blood tests to determine hematological inflammation biomarkers. Results. Occult PsA patients had a higher derived neutrophil-to-lymphocyte ratio (dNLR) (1.6 (1.3–2.2) vs. 1.3 (0.9–1.8), < 0.001), body mass index (BMI) (25.2 (23.7–28.1) vs. 24.0 (21.9–26.0), = 0.002), diabetes mellitus (DM) rate (30.3% vs. 7.2%, < 0.001), and nail involvement rate (65.2% vs. 41.0%, = 0.003) than patients with PsO alone. A prediction nomogram was established, and the area under the curve (AUC) was 0.843. The sensitivity and specificity of the model for identifying occult PsA patients were 77.3% and 81.9%, respectively. Conclusion. Our findings suggest that dNLR is a valuable diagnostic biomarker for occult PsA, and our prediction nomogram could provide clinicians with a useful tool for differentiating occult PsA patients from PsO alone patients.
{"title":"The Clinical Significance of the Derived Neutrophil-to-Lymphocyte Ratio in Differentiating Occult Psoriatic Arthritis from Psoriasis Alone","authors":"Yingyuan Yu, Dawei Huang, Yuxiong Jiang, Jiajing Lu, Lian Cui, Rongfen Chen, Ying Li, Yuling Shi","doi":"10.1155/2023/6680536","DOIUrl":"https://doi.org/10.1155/2023/6680536","url":null,"abstract":"Background. Occult psoriatic arthritis (PsA) refers to a subset of psoriasis patients showing lesions on imaging but do not exhibit arthritis symptoms. Objective. This study was aimed to discover a simple biomarker that could be easily incorporated in clinical practice to identify occult PsA patients, defined as psoriasis patients with lesions on imaging but without arthritis symptoms, among silent psoriasis (PsO) patients, defined as psoriasis patients without any arthritis symptoms. Methods. A total of 149 silent PsO patients, including 83 PsO alone patients, defined as psoriasis patients without any arthritis symptoms and evidence of lesions on imaging, and 66 occult PsA patients, were enrolled in this cross-sectional study, and they all underwent blood tests to determine hematological inflammation biomarkers. Results. Occult PsA patients had a higher derived neutrophil-to-lymphocyte ratio (dNLR) (1.6 (1.3–2.2) vs. 1.3 (0.9–1.8), <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> </math> < 0.001), body mass index (BMI) (25.2 (23.7–28.1) vs. 24.0 (21.9–26.0), <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> </math> = 0.002), diabetes mellitus (DM) rate (30.3% vs. 7.2%, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> </math> < 0.001), and nail involvement rate (65.2% vs. 41.0%, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> </math> = 0.003) than patients with PsO alone. A prediction nomogram was established, and the area under the curve (AUC) was 0.843. The sensitivity and specificity of the model for identifying occult PsA patients were 77.3% and 81.9%, respectively. Conclusion. Our findings suggest that dNLR is a valuable diagnostic biomarker for occult PsA, and our prediction nomogram could provide clinicians with a useful tool for differentiating occult PsA patients from PsO alone patients.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135938521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Amitay-Laish, H. Prag Naveh, R. Holzman, Ali Abo Baker, Adi Raviv, R. Friedland, D. Ben Amitai, O. Reiter, Michael David, E. Hodak
Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and for early-stage non-FMF refractory to narrow-band ultraviolet B (NBUVB). However, PUVA has a problematic safety profile. Literature on the treatment with the combination of UVA and NBUVB for MF is sparse. Objective. To evaluate the effectiveness of UVA combined with NBUVB for early-stage MF, specifically for FMF and NBUVB-refractory non-FMF, in adult and pediatric patients. Methods. A retrospective analysis was conducted for patients treated with UVA combined with NBUVB at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults and 16 pediatric patients. The overall response rate (ORR) of 39 patients with early-FMF (25 adults and 14 children) was 95%, and the complete response (CR) was 62%. No significant differences in ORR/CR rates were noted between adult and pediatric patients. Of 12 patients with non-FMF (10 adults and 2 children), the ORR was 83% and the CR was 50%. In 17 patients (8 FMF and 9 non-FMF), prior NBUVB therapy resulted in partial response/stable disease; yet, UVA + NBUVB led to CR in 9 patients (4 FMF and 5 non-FMF). Side effects were minimal. Conclusion. Combined UVA and NBUVB is a good alternative to PUVA for adult or pediatric patients with early-stage MF , with FMF or non-FMF refractory to NBUVB.
{"title":"Ultraviolet A Combined with Narrow-Band Ultraviolet B is an Effective Treatment Modality for Early Folliculotropic Mycosis Fungoides and Early Mycosis Fungoides Refractory to Narrow-Band Ultraviolet B: A Retrospective Cohort Study","authors":"I. Amitay-Laish, H. Prag Naveh, R. Holzman, Ali Abo Baker, Adi Raviv, R. Friedland, D. Ben Amitai, O. Reiter, Michael David, E. Hodak","doi":"10.1155/2023/8865065","DOIUrl":"https://doi.org/10.1155/2023/8865065","url":null,"abstract":"Background. Psoralen plus ultraviolet A (PUVA) is the preferred phototherapeutic modality for early-stage folliculotropic mycosis fungoides (FMF), and for early-stage non-FMF refractory to narrow-band ultraviolet B (NBUVB). However, PUVA has a problematic safety profile. Literature on the treatment with the combination of UVA and NBUVB for MF is sparse. Objective. To evaluate the effectiveness of UVA combined with NBUVB for early-stage MF, specifically for FMF and NBUVB-refractory non-FMF, in adult and pediatric patients. Methods. A retrospective analysis was conducted for patients treated with UVA combined with NBUVB at our center, during 1/2008–8/2022. Results. The cohort included 51 patients: 35 adults and 16 pediatric patients. The overall response rate (ORR) of 39 patients with early-FMF (25 adults and 14 children) was 95%, and the complete response (CR) was 62%. No significant differences in ORR/CR rates were noted between adult and pediatric patients. Of 12 patients with non-FMF (10 adults and 2 children), the ORR was 83% and the CR was 50%. In 17 patients (8 FMF and 9 non-FMF), prior NBUVB therapy resulted in partial response/stable disease; yet, UVA + NBUVB led to CR in 9 patients (4 FMF and 5 non-FMF). Side effects were minimal. Conclusion. Combined UVA and NBUVB is a good alternative to PUVA for adult or pediatric patients with early-stage MF , with FMF or non-FMF refractory to NBUVB.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47121334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Arabzadeh Bahri, Saba Maleki, Arman Shafiee, N. Ghandi, R. Abedini, A. Ehsani, Ala Ehsani, Z. Razavi
Objectives. To determine the efficacy of platelet-rich plasma in treating alopecia areata. Methods. A systematic search was carried out in PubMed, Embase, and the Cochrane Library databases to identify any article evaluating the efficacy of platelet-rich plasma for the treatment of alopecia areata and comparing platelet-rich plasma with other treatment modalities. Results. Nine studies were included based on our inclusion criteria with a total of 616 patients. Various evaluations of alopecia areata treatment efficacy with platelet-rich plasma, including the comparison between platelet-rich plasma and triamcinolone acetonide, minoxidil, placebo, and other methods, such as fractional carbon dioxide laser and microneedling, were conducted in the included studies. The main results revealed that platelet-rich plasma and triamcinolone acetonide are both effective in the treatment of alopecia areata. However, the treatment response was in favor of platelet-rich plasma. Also, minoxidil showed positive effects on the treatment of alopecia areata alongside platelet-rich plasma. Platelet-rich plasma also has significantly better effects on alopecia areata compared to placebo. Most of the side effects of treatment of alopecia areata with platelet-rich plasma were minor, including burning sensation, pain during injection, erythema, edema, ecchymosis, crust formation, and headache. Conclusion. Based on the evidence reviewed, it is suggested that platelet-rich plasma is a safe and effective treatment option for alopecia areata. Furthermore, platelet-rich plasma has the advantage of being a steroid-sparing therapy, reducing the reliance on corticosteroids. The use of platelet-rich plasma is associated with fewer complications compared to other treatment modalities.
{"title":"Efficacy and Safety of Platelet-Rich Plasma Therapy in Alopecia Areata Patients: A Systematic Review","authors":"R. Arabzadeh Bahri, Saba Maleki, Arman Shafiee, N. Ghandi, R. Abedini, A. Ehsani, Ala Ehsani, Z. Razavi","doi":"10.1155/2023/8827644","DOIUrl":"https://doi.org/10.1155/2023/8827644","url":null,"abstract":"Objectives. To determine the efficacy of platelet-rich plasma in treating alopecia areata. Methods. A systematic search was carried out in PubMed, Embase, and the Cochrane Library databases to identify any article evaluating the efficacy of platelet-rich plasma for the treatment of alopecia areata and comparing platelet-rich plasma with other treatment modalities. Results. Nine studies were included based on our inclusion criteria with a total of 616 patients. Various evaluations of alopecia areata treatment efficacy with platelet-rich plasma, including the comparison between platelet-rich plasma and triamcinolone acetonide, minoxidil, placebo, and other methods, such as fractional carbon dioxide laser and microneedling, were conducted in the included studies. The main results revealed that platelet-rich plasma and triamcinolone acetonide are both effective in the treatment of alopecia areata. However, the treatment response was in favor of platelet-rich plasma. Also, minoxidil showed positive effects on the treatment of alopecia areata alongside platelet-rich plasma. Platelet-rich plasma also has significantly better effects on alopecia areata compared to placebo. Most of the side effects of treatment of alopecia areata with platelet-rich plasma were minor, including burning sensation, pain during injection, erythema, edema, ecchymosis, crust formation, and headache. Conclusion. Based on the evidence reviewed, it is suggested that platelet-rich plasma is a safe and effective treatment option for alopecia areata. Furthermore, platelet-rich plasma has the advantage of being a steroid-sparing therapy, reducing the reliance on corticosteroids. The use of platelet-rich plasma is associated with fewer complications compared to other treatment modalities.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44726969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anqi Sheng, Miaoni Zhou, Wenting Hu, Rong Jin, Ke Bian, You Hua, Fuquan Lin, Ai’e Xu
Background. Acne is a prevalent skin disorder that primarily affects seborrheic areas. It occurs due to hair follicle obstruction and subsequent inflammation. Patients with acne often exhibit compromised skin barrier function and sensitivity, making treatment challenging. Objectives. This study aimed to investigate the occurrence of acne complicated by sensitive skin and explore the associated physiological changes. Methods. The lactic acid test and capsaicin test were employed to identify subjects with simple acne and those with acne and sensitive skin. Physiological characteristics were assessed in both groups. Two random groups were selected from the subjects with acne and sensitive skin. One group received treatment for acne alone, while the other group received combined treatment for acne and sensitive skin care. The efficacy and physiological function of the two groups were compared after treatment. Results. Among 170 acne patients, 99 were identified as having acne with sensitive skin. Patients with acne and sensitive skin exhibited significantly higher scores on the lactic acid test and capsaicin test compared to those with simple acne. They also showed increased transepidermal water loss (TEWL), decreased skin cuticle hydration (SCH), thinner epidermis, and thicker blood vessels. The group receiving combined treatment demonstrated a more significant reduction in the number of skin lesions and IGA scores compared to the group receiving treatment for acne alone. They also exhibited lower scores on the lactate and capsaicin tests, along with decreases in TEWL and increases in SCH. Conclusions. Acne with sensitive skin is highly prevalent and is associated with distinct physiological characteristics. Combined treatment targeting both acne and sensitive skin yields excellent clinical outcomes and improves skin’s physiological function. These findings underscore the importance of considering sensitive skin in the clinical management of acne.
{"title":"Clinical Characteristics and Treatment of Acne with Sensitive Skin","authors":"Anqi Sheng, Miaoni Zhou, Wenting Hu, Rong Jin, Ke Bian, You Hua, Fuquan Lin, Ai’e Xu","doi":"10.1155/2023/6528850","DOIUrl":"https://doi.org/10.1155/2023/6528850","url":null,"abstract":"Background. Acne is a prevalent skin disorder that primarily affects seborrheic areas. It occurs due to hair follicle obstruction and subsequent inflammation. Patients with acne often exhibit compromised skin barrier function and sensitivity, making treatment challenging. Objectives. This study aimed to investigate the occurrence of acne complicated by sensitive skin and explore the associated physiological changes. Methods. The lactic acid test and capsaicin test were employed to identify subjects with simple acne and those with acne and sensitive skin. Physiological characteristics were assessed in both groups. Two random groups were selected from the subjects with acne and sensitive skin. One group received treatment for acne alone, while the other group received combined treatment for acne and sensitive skin care. The efficacy and physiological function of the two groups were compared after treatment. Results. Among 170 acne patients, 99 were identified as having acne with sensitive skin. Patients with acne and sensitive skin exhibited significantly higher scores on the lactic acid test and capsaicin test compared to those with simple acne. They also showed increased transepidermal water loss (TEWL), decreased skin cuticle hydration (SCH), thinner epidermis, and thicker blood vessels. The group receiving combined treatment demonstrated a more significant reduction in the number of skin lesions and IGA scores compared to the group receiving treatment for acne alone. They also exhibited lower scores on the lactate and capsaicin tests, along with decreases in TEWL and increases in SCH. Conclusions. Acne with sensitive skin is highly prevalent and is associated with distinct physiological characteristics. Combined treatment targeting both acne and sensitive skin yields excellent clinical outcomes and improves skin’s physiological function. These findings underscore the importance of considering sensitive skin in the clinical management of acne.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135420641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eva María Arias, Gerald Selda-Enríquez, Patricia Burgos-Blasco, Ana Melián-Olivera, Sara Manzanares, Eduard Sarró, Núria Floriach, David Saceda-Corralo
Introduction. Androgenetic alopecia (AGA), the most common form of hair loss in women, is characterized by progressive hair thinning and loss of terminal hairs over frontal and parietal regions of the scalp. This study aimed to evaluate the efficacy of the nutritional supplement Pilopeptan® WOMAN 5αR (PPT5α) composed of specific plant extracts, vitamins, and minerals in women with initial to moderate AGA. Methods. This was a prospective, randomized, double-blind, placebo-controlled clinical trial study. Forty-seven women (aged 25–59 years) with AGA grade I/II were randomized to daily receive PPT5α (n = 24) or placebo (n = 23), and the treatment safety, as well as the percentages of terminal hair in frontal and parietal areas from trichoscopic images, was assessed at 0, 3, and 6 months. Secondary outcomes included self-assessed hair parameters and overall treatment satisfaction. Results. A total of 44 women completed the study. At 6 months, patients who received the nutritional supplement showed high percentages of terminal hair both in the frontal (77.6% vs 69.8%, ) and parietal (77% vs 64.3%, ) areas compared to the placebo group. Self-assessed evaluation of hair parameters showed an improvement in the reduction of hair loss and hair thickness both at the 3-month ( and ) and 6-month ( and ) visits. At the 3 month visit, the intervention group also showed higher treatment satisfaction . No significant adverse events were reported. Conclusion. These results evidence that the nutritional supplement PPT5α may be beneficial in preventing progression or even improving the condition of AGA in the early stages.
{"title":"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of a Nutritional Supplement in Female Androgenic Alopecia","authors":"Eva María Arias, Gerald Selda-Enríquez, Patricia Burgos-Blasco, Ana Melián-Olivera, Sara Manzanares, Eduard Sarró, Núria Floriach, David Saceda-Corralo","doi":"10.1155/2023/3527895","DOIUrl":"https://doi.org/10.1155/2023/3527895","url":null,"abstract":"Introduction. Androgenetic alopecia (AGA), the most common form of hair loss in women, is characterized by progressive hair thinning and loss of terminal hairs over frontal and parietal regions of the scalp. This study aimed to evaluate the efficacy of the nutritional supplement Pilopeptan® WOMAN 5αR (PPT5α) composed of specific plant extracts, vitamins, and minerals in women with initial to moderate AGA. Methods. This was a prospective, randomized, double-blind, placebo-controlled clinical trial study. Forty-seven women (aged 25–59 years) with AGA grade I/II were randomized to daily receive PPT5α (n = 24) or placebo (n = 23), and the treatment safety, as well as the percentages of terminal hair in frontal and parietal areas from trichoscopic images, was assessed at 0, 3, and 6 months. Secondary outcomes included self-assessed hair parameters and overall treatment satisfaction. Results. A total of 44 women completed the study. At 6 months, patients who received the nutritional supplement showed high percentages of terminal hair both in the frontal (77.6% vs 69.8%, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M1\"> <mi>p</mi> <mo>=</mo> <mn>0.02</mn> </math> ) and parietal (77% vs 64.3%, <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M2\"> <mi>p</mi> <mo>=</mo> <mn>0.02</mn> </math> ) areas compared to the placebo group. Self-assessed evaluation of hair parameters showed an improvement in the reduction of hair loss and hair thickness both at the 3-month ( <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M3\"> <mi>p</mi> <mo>=</mo> <mn>0.004</mn> </math> and <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M4\"> <mi>p</mi> <mo>=</mo> <mn>0.012</mn> </math> ) and 6-month ( <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M5\"> <mi>p</mi> <mo>=</mo> <mn>0.009</mn> </math> and <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M6\"> <mi>p</mi> <mo>=</mo> <mn>0.004</mn> </math> ) visits. At the 3 month visit, the intervention group also showed higher treatment satisfaction <math xmlns=\"http://www.w3.org/1998/Math/MathML\" id=\"M7\"> <mfenced open=\"(\" close=\")\" separators=\"|\"> <mrow> <mi>p</mi> <mo>=</mo> <mn>0.01</mn> </mrow> </mfenced> </math> . No significant adverse events were reported. Conclusion. These results evidence that the nutritional supplement PPT5α may be beneficial in preventing progression or even improving the condition of AGA in the early stages.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135771420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The primary aim of this retrospective study was to investigate the potential effectiveness of autologous platelet gel as a method for facial volume restoration and skin rejuvenation. High-frequency ultrasonography was utilized to assess the outcomes of the treatment. The study included a cohort of ten female patients aged between 40 and 50 who actively participated in the research. They reported moderate-to-severe static and dynamic wrinkles, volume loss, thinning, and roughness of the skin. Each patient received one session of autologous platelet gel injections. The gel was prepared accordingly with the manufacturer’s (INNMEDIS, ATR™) instructions. Medium viscosity gel was injected into the superficial subdermal fat pads in the temples, as well as in the middle and lower face areas, to improve facial volume. A high-frequency ultrasound (US) device was employed to quantify skin density, skin thickness, and the depth of nasolabial folds. The US images were captured at three time points: before gel administration, one month after the procedure, and three months after the procedure. The imaging focused on the nasolabial folds area to monitor changes and assess the effectiveness of the treatment over time. Based on the analyses, the use of autologous platelet gel is beneficial towards improving skin density and decreasing nasolabial fold depth. However, further research should be conducted into the gel’s effects on dermis thickness to achieve a stronger, more statistically significant conclusion. The level of satisfaction of the enrolled patients regarding their facial appearance was evaluated using the visual analogue scale (VAS). The VAS assessment revealed an average score of 4.1 before the commencement of the treatment, an average score of 7.9 one month after the treatment, and an average score of 7.5 three months following the treatment. The results indicate a significant increase in patient satisfaction following treatment completion. Autologous platelet gel appears to hold promise as a treatment option for volume replacement and skin rejuvenation, making it an attractive choice for individuals seeking natural skin treatments. Despite the encouraging findings from this observation, further validation is required through a larger controlled study to definitively confirm whether autologous platelet gel is indeed an effective method for volume replacement and skin rejuvenation.
{"title":"Autologous Plasma Gel as an Effective Method of Facial Volume Restoration and Skin Rejuvenation","authors":"Lidia Majewska","doi":"10.1155/2023/9989544","DOIUrl":"https://doi.org/10.1155/2023/9989544","url":null,"abstract":"The primary aim of this retrospective study was to investigate the potential effectiveness of autologous platelet gel as a method for facial volume restoration and skin rejuvenation. High-frequency ultrasonography was utilized to assess the outcomes of the treatment. The study included a cohort of ten female patients aged between 40 and 50 who actively participated in the research. They reported moderate-to-severe static and dynamic wrinkles, volume loss, thinning, and roughness of the skin. Each patient received one session of autologous platelet gel injections. The gel was prepared accordingly with the manufacturer’s (INNMEDIS, ATR™) instructions. Medium viscosity gel was injected into the superficial subdermal fat pads in the temples, as well as in the middle and lower face areas, to improve facial volume. A high-frequency ultrasound (US) device was employed to quantify skin density, skin thickness, and the depth of nasolabial folds. The US images were captured at three time points: before gel administration, one month after the procedure, and three months after the procedure. The imaging focused on the nasolabial folds area to monitor changes and assess the effectiveness of the treatment over time. Based on the analyses, the use of autologous platelet gel is beneficial towards improving skin density and decreasing nasolabial fold depth. However, further research should be conducted into the gel’s effects on dermis thickness to achieve a stronger, more statistically significant conclusion. The level of satisfaction of the enrolled patients regarding their facial appearance was evaluated using the visual analogue scale (VAS). The VAS assessment revealed an average score of 4.1 before the commencement of the treatment, an average score of 7.9 one month after the treatment, and an average score of 7.5 three months following the treatment. The results indicate a significant increase in patient satisfaction following treatment completion. Autologous platelet gel appears to hold promise as a treatment option for volume replacement and skin rejuvenation, making it an attractive choice for individuals seeking natural skin treatments. Despite the encouraging findings from this observation, further validation is required through a larger controlled study to definitively confirm whether autologous platelet gel is indeed an effective method for volume replacement and skin rejuvenation.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47178103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Park, S. Y. Lee, Jin Cheol Kim, C. Park, H. Kim, B. Chung
Facial erythema is a representative symptom of rosacea patients that greatly impairs quality of life. Recently, the therapeutic effects of intradermal injection of botulinum toxin type-A on erythema have been investigated. Fractional microneedling radiofrequency has been reported to be effective in dermal remodeling and anti-inflammation. To obtain enhanced therapeutic effects with a less painful and easier approach, a treatment regimen using transdermal botulinum toxin delivery with fractional microneedling radiofrequency was developed. We aimed at investigating the efficacy and safety of transdermal botulinum toxin delivery with fractional microneedling radiofrequency in treating the erythema of rosacea. This was a retrospective review of 20 patients with facial erythema associated with rosacea. All patients underwent two sessions of treatment at 4-week intervals. Standardized photographs were taken, and the clinicians' erythema assessment (CEA), erythema index (EI) measured through a spectrophotometer, investigator’s global assessment (IGA), and subjective satisfaction and side effects were evaluated at the baseline and 4, 8, and 12 weeks after the baseline. Compared to the baseline, CEA levels significantly decreased after 8 weeks ( P = 0.018 ) and 12 weeks ( P = 0.005 ). As an objective measure, EI was observed to decrease significantly at 4 weeks ( P = 0.04 ) and 8 weeks after the baseline ( P = 0.005 ) compared with the baseline. Ninety-five percent of patients were either very satisfied or satisfied with the treatment. None of the patients experienced remarkable side effects. A novel treatment regimen involving transdermal botulinum toxin delivery and fractional microneedling radiofrequency may be an effective and safe option for reducing the facial erythema of rosacea.
{"title":"A Novel Regimen of Transdermal Botulinum Toxin Delivery Using Fractional Microneedling Radiofrequency for Treatment of Erythema in Rosacea","authors":"J. Park, S. Y. Lee, Jin Cheol Kim, C. Park, H. Kim, B. Chung","doi":"10.1155/2023/8838206","DOIUrl":"https://doi.org/10.1155/2023/8838206","url":null,"abstract":"Facial erythema is a representative symptom of rosacea patients that greatly impairs quality of life. Recently, the therapeutic effects of intradermal injection of botulinum toxin type-A on erythema have been investigated. Fractional microneedling radiofrequency has been reported to be effective in dermal remodeling and anti-inflammation. To obtain enhanced therapeutic effects with a less painful and easier approach, a treatment regimen using transdermal botulinum toxin delivery with fractional microneedling radiofrequency was developed. We aimed at investigating the efficacy and safety of transdermal botulinum toxin delivery with fractional microneedling radiofrequency in treating the erythema of rosacea. This was a retrospective review of 20 patients with facial erythema associated with rosacea. All patients underwent two sessions of treatment at 4-week intervals. Standardized photographs were taken, and the clinicians' erythema assessment (CEA), erythema index (EI) measured through a spectrophotometer, investigator’s global assessment (IGA), and subjective satisfaction and side effects were evaluated at the baseline and 4, 8, and 12 weeks after the baseline. Compared to the baseline, CEA levels significantly decreased after 8 weeks (\u0000 \u0000 P\u0000 =\u0000 0.018\u0000 \u0000 ) and 12 weeks (\u0000 \u0000 P\u0000 =\u0000 0.005\u0000 \u0000 ). As an objective measure, EI was observed to decrease significantly at 4 weeks (\u0000 \u0000 P\u0000 =\u0000 0.04\u0000 \u0000 ) and 8 weeks after the baseline (\u0000 \u0000 P\u0000 =\u0000 0.005\u0000 \u0000 ) compared with the baseline. Ninety-five percent of patients were either very satisfied or satisfied with the treatment. None of the patients experienced remarkable side effects. A novel treatment regimen involving transdermal botulinum toxin delivery and fractional microneedling radiofrequency may be an effective and safe option for reducing the facial erythema of rosacea.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47600705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Barzilai, Theodoulos Drousiotis, A. Dalal, F. Pavlotsky, A. Shemer, S. Baum
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease affecting approximately 25% of all people worldwide at some point during their lifetime. Although total serum immunoglobulin E (IgE) and blood eosinophil levels are not elevated in all patients with AD, they have been shown associated with AD severity. This study aimed to investigate whether IgE and blood eosinophil levels correlate with the response to phototherapy treatment, which is a second-line treatment for moderate-to-severe AD, and therefore could be considered a readily available and reliable biomarker that could guide patient management. Eighty-two patients with AD who received phototherapy at the Sheba Medical Center were retrospectively evaluated for the following: demographic characteristics, serum IgE levels, blood eosinophils count, hospitalization duration, response to phototherapy, and requirement for systemic treatment. Response to phototherapy treatment was assessed by comparing the pre- and post-treatment Investigator’s Global Assessment score for each patient in relation to the aforementioned factors. The total IgE and eosinophil levels were found to be significantly higher in patients who did not respond to phototherapy ( p = 0.018 and p = 0.002 , accordingly). Serum values of 1780 IU/mL for IgE and 225.0 cells/μL for eosinophils showed maximum sensitivity and specificity as predictive values for treatment response. In conclusion, this study found that high total serum IgE levels and eosinophilia were correlated with a low response to phototherapy. These results suggest that escalating treatment is recommended for patients presenting these clinical features.
{"title":"The Combination of Serum Total IgE and Blood Eosinophil Levels as a Predictor of Response to Phototherapy Treatment in Patients with Atopic Dermatitis","authors":"A. Barzilai, Theodoulos Drousiotis, A. Dalal, F. Pavlotsky, A. Shemer, S. Baum","doi":"10.1155/2023/9969530","DOIUrl":"https://doi.org/10.1155/2023/9969530","url":null,"abstract":"Atopic dermatitis (AD) is the most common chronic inflammatory skin disease affecting approximately 25% of all people worldwide at some point during their lifetime. Although total serum immunoglobulin E (IgE) and blood eosinophil levels are not elevated in all patients with AD, they have been shown associated with AD severity. This study aimed to investigate whether IgE and blood eosinophil levels correlate with the response to phototherapy treatment, which is a second-line treatment for moderate-to-severe AD, and therefore could be considered a readily available and reliable biomarker that could guide patient management. Eighty-two patients with AD who received phototherapy at the Sheba Medical Center were retrospectively evaluated for the following: demographic characteristics, serum IgE levels, blood eosinophils count, hospitalization duration, response to phototherapy, and requirement for systemic treatment. Response to phototherapy treatment was assessed by comparing the pre- and post-treatment Investigator’s Global Assessment score for each patient in relation to the aforementioned factors. The total IgE and eosinophil levels were found to be significantly higher in patients who did not respond to phototherapy (\u0000 \u0000 p\u0000 =\u0000 0.018\u0000 \u0000 and \u0000 \u0000 p\u0000 =\u0000 0.002\u0000 \u0000 , accordingly). Serum values of 1780 IU/mL for IgE and 225.0 cells/μL for eosinophils showed maximum sensitivity and specificity as predictive values for treatment response. In conclusion, this study found that high total serum IgE levels and eosinophilia were correlated with a low response to phototherapy. These results suggest that escalating treatment is recommended for patients presenting these clinical features.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44935120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Y. Lee, H. Kim, J. Park, Jin Cheol Kim, C. Park, H. Kim, B. Chung
Melasma is a challenging pigmentation disorder to treat, and although low-fluence 1064 nm picosecond ND-YAG lasers have shown potential for treating benign pigmented disorders, data on the use of this laser for melasma treatment are currently insufficient. In this prospective split-face study, twenty-four patients with melasma on the face were enrolled and randomly assigned to receive treatment on one side of the face either with a low-fluence 1064 nm picosecond ND-YAG laser or with a low-fluence PTP mode 1064 nm Q-switched ND-YAG laser. Laser treatment was performed 5 times at intervals of 2 weeks, with evaluation conducted before each treatment and 2 months after the completion of 5 treatments. Clinical pictures using a standardized, digital photographic system and dermoscopy were taken on each day of the visit. The modified melasma area severity index (mMASI), melanin index (MI), dermoscopic scores of the pigmentary and vascular elements in melasma, pain during laser treatment, and patient satisfaction score were recorded. Twenty-one participants completed the study, and from week 2 in both groups, a significant decrease in mMASI and MI were confirmed. Although no statistically significant difference was observed, the decrease in mMASI and MI were greater in the 1064 nm picosecond ND-YAG laser group than in the 1064 nm Q-switched ND-YAG laser group. The 1064 nm picosecond ND-YAG laser group showed significant improvement in the pseudoreticular network and globular pattern of dermoscopic features between week 0 and week 16, while significant improvement in the globular pattern was shown in the 1064 nm Q-switched ND-YAG laser group. No significant difference was observed between the two groups in terms of the patient satisfaction score and pain during laser treatments. Notably, no adverse events were observed in either group. In conclusion, our study demonstrated that a low-fluence 1064 nm picosecond ND-YAG laser is as effective and safe in the treatment of melasma as a low-fluence PTP mode 1064 nm Q-switched ND-YAG laser.
{"title":"The Efficacy and Safety of a Low-Fluence 1064 nm Picosecond ND-YAG Laser Compared with Those of a Low-Fluence Photoacoustic Therapy Pulsed (PTP) Mode 1064 nm Q-Switched ND-YAG Laser for Treatment of Melasma: A Prospective Split-Face Study","authors":"S. Y. Lee, H. Kim, J. Park, Jin Cheol Kim, C. Park, H. Kim, B. Chung","doi":"10.1155/2023/5961152","DOIUrl":"https://doi.org/10.1155/2023/5961152","url":null,"abstract":"Melasma is a challenging pigmentation disorder to treat, and although low-fluence 1064 nm picosecond ND-YAG lasers have shown potential for treating benign pigmented disorders, data on the use of this laser for melasma treatment are currently insufficient. In this prospective split-face study, twenty-four patients with melasma on the face were enrolled and randomly assigned to receive treatment on one side of the face either with a low-fluence 1064 nm picosecond ND-YAG laser or with a low-fluence PTP mode 1064 nm Q-switched ND-YAG laser. Laser treatment was performed 5 times at intervals of 2 weeks, with evaluation conducted before each treatment and 2 months after the completion of 5 treatments. Clinical pictures using a standardized, digital photographic system and dermoscopy were taken on each day of the visit. The modified melasma area severity index (mMASI), melanin index (MI), dermoscopic scores of the pigmentary and vascular elements in melasma, pain during laser treatment, and patient satisfaction score were recorded. Twenty-one participants completed the study, and from week 2 in both groups, a significant decrease in mMASI and MI were confirmed. Although no statistically significant difference was observed, the decrease in mMASI and MI were greater in the 1064 nm picosecond ND-YAG laser group than in the 1064 nm Q-switched ND-YAG laser group. The 1064 nm picosecond ND-YAG laser group showed significant improvement in the pseudoreticular network and globular pattern of dermoscopic features between week 0 and week 16, while significant improvement in the globular pattern was shown in the 1064 nm Q-switched ND-YAG laser group. No significant difference was observed between the two groups in terms of the patient satisfaction score and pain during laser treatments. Notably, no adverse events were observed in either group. In conclusion, our study demonstrated that a low-fluence 1064 nm picosecond ND-YAG laser is as effective and safe in the treatment of melasma as a low-fluence PTP mode 1064 nm Q-switched ND-YAG laser.","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48839503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：